Matches in DBpedia 2016-04 for { ?s ?p "Brivaracetam, the 4-n-propyl analog of levetiracetam, is a racetam derivative with anticonvulsant properties. Brivaracetam is believed to act by binding to the ubiquitous synaptic vesicle glycoprotein 2A (SV2A). Phase II clinical trials in adult patients with refractory partial seizures were promising. Positive preliminary results from stage III trials have been recorded, along with evidence that it is around 10 times more potent for the prevention of certain types of seizure in mouse models than levetiracetam, of which it is an analogue.On 14 January 2016, the European Commission, and on 18 February 2016, the USFDA approved brivaracetam under the trade name Briviact (by UCB). The launch of this anti-epileptic is scheduled for the first quarter of that year. Currently, brivaracetam is still not approved in other countries like Australia, Canada and Switzerland."@en }
Showing triples 1 to 2 of
2
with 100 triples per page.
- Brivaracetam abstract "Brivaracetam, the 4-n-propyl analog of levetiracetam, is a racetam derivative with anticonvulsant properties. Brivaracetam is believed to act by binding to the ubiquitous synaptic vesicle glycoprotein 2A (SV2A). Phase II clinical trials in adult patients with refractory partial seizures were promising. Positive preliminary results from stage III trials have been recorded, along with evidence that it is around 10 times more potent for the prevention of certain types of seizure in mouse models than levetiracetam, of which it is an analogue.On 14 January 2016, the European Commission, and on 18 February 2016, the USFDA approved brivaracetam under the trade name Briviact (by UCB). The launch of this anti-epileptic is scheduled for the first quarter of that year. Currently, brivaracetam is still not approved in other countries like Australia, Canada and Switzerland.".
- Q408099 abstract "Brivaracetam, the 4-n-propyl analog of levetiracetam, is a racetam derivative with anticonvulsant properties. Brivaracetam is believed to act by binding to the ubiquitous synaptic vesicle glycoprotein 2A (SV2A). Phase II clinical trials in adult patients with refractory partial seizures were promising. Positive preliminary results from stage III trials have been recorded, along with evidence that it is around 10 times more potent for the prevention of certain types of seizure in mouse models than levetiracetam, of which it is an analogue.On 14 January 2016, the European Commission, and on 18 February 2016, the USFDA approved brivaracetam under the trade name Briviact (by UCB). The launch of this anti-epileptic is scheduled for the first quarter of that year. Currently, brivaracetam is still not approved in other countries like Australia, Canada and Switzerland.".